Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 152-159

  Huynh, Hung ^a   Lee, Jonathan W J ^a,d   Chow, Pierce K H ^b,c   Ngo, Van Chanh ^a   Guo, Bin Lew ^a   Lam, Irene W L ^a   Hock, Soo Ong ^b   Chung, Alexander ^b   Khee, Chee Soo ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P15; PROTEIN P21; PROTEIN P27; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXPERIMENTAL MODEL; GASTROINTESTINAL STROMAL TUMOR; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BENZENESULFONATES; BODY WEIGHT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXONS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIDINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149511920     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0553     Document Type: Article

References (33)

1. Connolly E, Gaffney E, Reynolds J. Gastrointestinal stromal tumors. Br J Surg 2003;90:1178-86.
2. Tran T, Davila J, El-Serag H. The epidemiology of malignant gastrointestinal stromal tumours: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162-8.
3. DeMatteo R, Lewis J, Leung D, Mudan S, Woodruff J, Brennan M. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
4. Reddy P, Boci K, Charbonneau C. The epidemiologic, health-related quality of life and economic burden of gastrointestinal stromal tumors. J Clin Pharm Ther 2007;32:557-65.
5. Nilsson B, Bumming P, Meis-Kindblom J, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course and prognostication in preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821-9.
6. Gold J, DeMatteo RP. Combined surgical and molecular therapy - the gastrointestinal stromal tumor model. Ann Surg 2006;244:176-84.
7. Van der Zwan S, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005;104:1781-8.
8. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-9.
9. Crosby J, Catton C, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50-9.
10. Ng E, Pollock R, Romsdahl M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69:1334-41.
11. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
12. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in GIST. Science 2003;299:708-10.
13. Rubin B, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumor. Cancer Res 2001;61:8118-21.
14. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006;17:x280-6.
15. Corless C, Fletcher J, Heinrich M. Biology of gastrointestinal tumors. J Clin Oncol 2004;22:3813-25.
16. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
17. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
18. Van Glabbeke M, Verweij J, Casali P, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin Oncol 2005;23:5795-804.
19. Heinrich MC, Corless C, Blanke C, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74.
20. Sleijfer S, Wiemer E, Verweij J. Drug insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer specific treatment. Nat Clin Pract Oncol 2008;5:102-11.
21. Debiec-Rychter M, Scoit R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 2006;42:1093-103.
22. Demetri G, van Oosterom A, Garrett C, et al. Efficacy and safety of sunitinib in patients with advanced GISTs after failure of imatinib: a randomized controlled trial. Lancet 2006;368:1329-38.
23. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumors. Cancer Treat Rev 2008;34:37-48.
24. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
25. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
26. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KIT T670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13:4874-81.
27. Ratain M, Flaherty K, Stadler W, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [abstract 4501]. Proc Am Soc Clin Oncol Annu Meet 2004;22:14S.
28. Nimeiri HS, Maki RG, Kasza K, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstract 7]. American Society of Clinical Oncology 2008 Gastrointest Cancers Symposium, January 25-27, 2008, Orlando, FL.
29. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006;12:4306-14.
30. Miwa S, Nakajima T, Murai Y, Takano Y, Sugiyama T. Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol 2008;43:531-7.
31. Carvalho S, E Silva A, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumors: overexpression without mutations? J Clin Pathol 2004;57:1075-9.
32. Nakamura N, Yamamoto H, Yao T, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005;36:828-37.
33. Blair SL, Al-Refaie WB, Wang-Rodriguez J, Behling C, Ali M, Moossa AR. Gastrointestinal stromal tumors express ras oncogene. Arch Surg 2005;140:543-8.